首頁
Stealth BioTherapeutics

7月 2026Stealth BioTherapeutics的市場佔有率分析

Developing new biotherapeutic treatments for patients with genetic mitochondrial diseases and common diseases of aging.

健康 > 生物技術和製藥

域名stealthbt.com

成立年份2007

僱員51 - 200

年度營收$15M - $25M

Stealth BioTherapeutics

Stealth BioTherapeutics（包含公司地區）

stealthbt.com

查看更多網站流量與參與度資訊

Stealth BioTherapeutics截至 7月 2026 的總收入為 15M - 25M

Stealth BioTherapeutics 熱門網域產生的總收入

Stealth BioTherapeutics 熱門網域 3 年內的總收入

Stealth BioTherapeutics 熱門網域的總收入

stealthbt.com15M - 25M

透過銷售情報查看更多內容

Stealth BioTherapeutics的熱門網域總造訪量

了解Stealth BioTherapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

stealthbt.com5.1K

透過銷售情報查看更多內容

Stealth BioTherapeutics的熱門網域平均造訪時長

分析Stealth BioTherapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

stealthbt.com00:00:34

透過銷售情報查看更多內容

Stealth BioTherapeutics的熱門網域平均頁面瀏覽量

了解Stealth BioTherapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

stealthbt.com1.81

透過銷售情報查看更多內容

Stealth BioTherapeutics按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

immunocore.com公司名Immunocore僱員201 - 500總部英國, Abingdon年度營收$200M - $500M訪問總量11.6K健康 > 生物技術和製藥

使用的熱門技術Stealth BioTherapeutics

这些是Stealth BioTherapeutics顶级域名使用的行业网站技术

付費廣告 (6)

DoubleClick

小工具 (5)

reCAPTCHA

社群 (4)

Google+ Platform

轉換與分析 (2)

Google Analytics

更多技術

9

檢視所有

新聞與訊號來自Stealth BioTherapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Stealth BioTherapeutics Inc. attended event International Meeting on Mitochondrial Pathology (Euromit) on May 31st '26.NEEDHAM, Mass., May 26, 2026 /PRNewswire/ - Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its planned presentations at the International Meeting on Mitochondrial Pathology (Euromit), which is being held May 31-June 4, 2026, in Angers, France.

新聞Stealth BioTherapeutics Inc. attends event Association for Research in Vision and Ophthalmology 2026 Annual Meeting.Stealth BioTherapeutics to present clinical data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting.

新聞Stealth BioTherapeutics Inc. hired David A. Brown as Chief Scientific Officer on Apr 8th '26.NEEDHAM, Mass., April 8, 2026 /PRNewswire/ - Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of David A. Brown, Ph.D., as the company's Chief Scientific Officer and a member of the executive team, effective immediately.